RT Journal Article
T1 Efficacy of 65% permethrin applied to dogs as a spot-on against Phlebotomus perniciosus
A1 Molina Moreno, Ricardo
A1 Espinosa Góngora, Carmen
A1 Gálvez Esteban, Rosa María
A1 Montoya Matute, Ana
A1 Descalzo, Miguel Ángel
A1 Jiménez Alonso, María Isabel
A1 Dado, Diana
A1 Miró Corrales, Guadalupe
AB Leishmania infantum is a protozoan parasite causing leishmaniosis, a visceral disease transmitted by the bites of sand flies. As the main reservoir of the parasite, dogs are the principal targets of control measures against this disease, which affects both humans and dogs. Several studies have revealed the usefulness of topical insecticide treatment (collars, spot-ons and sprays) in reducing the incidence and prevalence of L. infantum. The present study was designed to test the efficacy of 65% permethrin applied to dogs as a spot-on against the sand fly vector Phlebotomus perniciosus. The duration of the desired effects was also estimated to help design an optimal treatment regimen. Twelve dogs assigned to treatment (n = 6) and control (n = 6) groups were exposed to sand flies once a week over a seven-week period. Repellent and insecticidal efficacies were estimated and compared amongst the groups. Our findings indicate satisfactory repellent, or anti-feeding, effects lasting 3 weeks and short-term insecticidal effects lasting 2 weeks after initial application. Accordingly, we recommend the use of this product every 2–3 weeks during the active phlebotomine sand fly period to protect dogs against the bites of P. perniciosus.
PB Elsevier
SN 0304-4017
YR 2012
FD 2012
LK https://hdl.handle.net/20.500.14352/110230
UL https://hdl.handle.net/20.500.14352/110230
LA eng
NO Molina R, Espinosa-Góngora C, Gálvez R, Montoya A, Descalzo MA, Jiménez MI, Dado D, Miró G. (2012). Efficacy of 65% permethrin applied to dogs as a spot-on against Phlebotomus perniciosus. Veterinary Parasitology, 187(3-4):529-33.
NO Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.vetpar.2012.01.024.
DS Docta Complutense
RD 8 abr 2025